) the fluorescence ratio recorded at 800 s was subtracted from the fluorescence ratio recorded at 1700 s; the difference was then divided by the ratio recorded at 800 s and multiplied by 100%. GSK-7975A significantly, albeit incompletely, inhibited resting Ba 2+ influx (which is considered as a reflection of resting Ca 2+ influx). The cells were maintained in CCK-containing solution for 60 minutes and number of vacuoles counted. The procedure involving preincubation with GSK-7975A followed by washing before CCK application resulted in the significant inhibition of endocytic vacuole formation (reduction to 48 ± 9%, 3 experiments). The reduction was slightly smaller than in the experiment shown in Fig.1 (when GSK-7975A was continuously
) the fluorescence ratio recorded at 800 s was subtracted from the fluorescence ratio recorded at 1700 s; the difference was then divided by the ratio recorded at 800 s and multiplied by 100%. GSK-7975A significantly, albeit incompletely, inhibited resting Ba 2+ influx (which is considered as a reflection of resting Ca 2+ influx). Figure S2 . Reversibility of the effects of GSK-7975A and PD150606 on the formation of endocytic vacuoles The bar graph shows the numbers of vacuoles per cell, normalized to that formed as a result of CCK stimulation (second bar, 3 experiments). Approximately 30 cells were analyzed for each experiment described in this figure legend. 'Control' summarizes the results of measurements conducted on unstimulated cells (28 ± 6%, 3 experiments). The bar labels 'GSK-7975A+ Wash, CCK' summarizes the results of measurements in cells which were first treated with 10µM GSK-7975A (for 30 minutes), then washed by perfusion for approximately 5 minutes in standard extracellular solution (without agonist or inhibitor) and finally stimulated with CCK. The cells were maintained in CCK-containing solution for 60 minutes and number of vacuoles counted. The procedure involving preincubation with GSK-7975A followed by washing before CCK application resulted in the significant inhibition of endocytic vacuole formation (reduction to 48 ± 9%, 3 experiments). The reduction was slightly smaller than in the experiment shown in Fig.1 , calculated as the difference between the F340/F380 ratio at the end of experiment and just before the addition of CCK). The left part of the figure compares the normalised Ca 2+ plateau amplitudes at 1500s. CCK-induced Ca 2+ plateau (49 cells, an example trace for this type of measurements can be found in Figure 1A ) and the CCK-induced Ca2+ plateau following treatment with 10µM of GSK-7975A (applied from 700s till 1500s, 104 cells) are significantly different. The mean value of CCK-induced Ca 2+ plateau measured at 1500 s was used to normalise all measurements displayed on (C). The right part of the figure shows the Ca 2+ plateau amplitudes measured at 3000s. The CCK-induced Ca 2+ plateau did not substantially change between 1500s and 3000s. The next bar (hatched) summarises the Ca 2+ plateau measurements in the cells that were first treated with 10µM of GSK-7975A (applied from 700s till 1500s) and then continuously perfused (i.e. washed) with GSK-7975A-free CCK-containing solution (104 cells). The right bar (filled) summarises the Ca 2+ plateau measurements in the cells that were treated 10µM of GSK-7975A until 3000s (104 cells). The statistically significant differences in the amplitudes (compare the hatched bars labelled CCK, GSK-7975A (700s-1500s) for 1500s and 3000s graphs as well as bars labelled CCK, GSK-7975A (700s-1500s) and GSK-7975A (700s-3000s) for 3000 s graph) indicate the partial reversibility of GSK-7975A inhibition. were conducted for each of the described conditions). The amylase secretion was measured for a 30-minute period. GSK-7975A reduced the mean values of amylase release for basal secretion and for all tested concentrations of CCK but the difference was small and reached statistical significance only for 500pM CCK. PD150606 did not significantly change basal secretion or secretion at any tested CCK concentration. 
